Deborah A. Smith

6.8k total citations · 1 hit paper
119 papers, 5.0k citations indexed

About

Deborah A. Smith is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Deborah A. Smith has authored 119 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 36 papers in Molecular Biology and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Deborah A. Smith's work include Colorectal Cancer Treatments and Studies (20 papers), HER2/EGFR in Cancer Research (15 papers) and Cancer Treatment and Pharmacology (14 papers). Deborah A. Smith is often cited by papers focused on Colorectal Cancer Treatments and Studies (20 papers), HER2/EGFR in Cancer Research (15 papers) and Cancer Treatment and Pharmacology (14 papers). Deborah A. Smith collaborates with scholars based in United States, United Kingdom and Netherlands. Deborah A. Smith's co-authors include Janet Quinn, Brian A. Morgan, Alistair J. P. Brown, Susan M. Nicholls, Kevin M. Koch, Robert K. Wayne, Neil L. Spector, Andrew G. Stead, Katherine Ralls and Howard A. Burris and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Deborah A. Smith

112 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

2005 503 citations Howard A. Burris, Herbert I. Hurwitz et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Deborah A. Smith United States	36	1.6k	1.5k	806	751	658	119	5.0k
Youichi Suzuki Japan	25	2.4k 1.5×	897 0.6×	336 0.4×	491 0.7×	378 0.6×	78	5.9k
Jeffrey A. Engler United States	40	3.7k 2.4×	1.7k 1.1×	669 0.8×	332 0.4×	327 0.5×	97	7.4k
A. Bruce Lyons Australia	38	2.3k 1.5×	1.5k 1.0×	362 0.4×	230 0.3×	479 0.7×	102	8.2k
Nicholas E. Sherman United States	41	3.1k 1.9×	951 0.6×	342 0.4×	228 0.3×	506 0.8×	95	6.3k
Masato Orita Japan	7	3.1k 1.9×	1.2k 0.8×	513 0.6×	167 0.2×	217 0.3×	8	6.3k
William V. Williams United States	40	2.2k 1.4×	973 0.7×	228 0.3×	877 1.2×	541 0.8×	159	6.1k
Christian Beisel Switzerland	37	4.3k 2.7×	1.8k 1.2×	243 0.3×	515 0.7×	161 0.2×	79	7.2k
Timothy P. Cripe United States	48	2.5k 1.6×	2.1k 1.4×	452 0.6×	283 0.4×	241 0.4×	174	6.2k
Takao Sekiya Japan	35	3.9k 2.4×	1.9k 1.3×	578 0.7×	107 0.1×	186 0.3×	129	7.1k
Erik K. Flemington United States	51	4.2k 2.7×	3.5k 2.4×	213 0.3×	490 0.7×	316 0.5×	157	8.0k

Countries citing papers authored by Deborah A. Smith

Since Specialization

Citations

This map shows the geographic impact of Deborah A. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah A. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah A. Smith more than expected).

Fields of papers citing papers by Deborah A. Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah A. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah A. Smith. The network helps show where Deborah A. Smith may publish in the future.

Co-authorship network of co-authors of Deborah A. Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Deborah A. Smith. A scholar is included among the top collaborators of Deborah A. Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah A. Smith. Deborah A. Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Münster, Pamela N., Rahul Aggarwal, David S. Hong, et al.. (2015). First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clinical Cancer Research. 22(8). 1932–1939. 83 indexed citations

Spector, Neil L., Faith C. Robertson, Sarah Bacus, et al.. (2015). Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor. PLoS ONE. 10(11). e0142845–e0142845. 21 indexed citations

Rosenkoetter, Marlene M., et al.. (2014). Video Analysis Tool System. Nursing Administration Quarterly. 38(4). E11–E22. 5 indexed citations

Fries, Ryan, et al.. (2013). Student and Faculty Perceptions on Plus-Minus Grading: A Case Study. Educational research quarterly. 36(4). 49–68. 1 indexed citations

Patterson, Miranda, Christopher McKenzie, Deborah A. Smith, et al.. (2013). Ybp1 and Gpx3 Signaling in Candida albicans Govern Hydrogen Peroxide-Induced Oxidation of the Cap1 Transcription Factor and Macrophage Escape. Antioxidants and Redox Signaling. 19(18). 2244–2260. 63 indexed citations

Olmos, David, Douglas S. Barker, Rohini Sharma, et al.. (2011). Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 17(10). 3420–3430. 134 indexed citations

MacCallum, Donna M., et al.. (2011). MAPKKK-independent Regulation of the Hog1 Stress-activated Protein Kinase in Candida albicans. Journal of Biological Chemistry. 286(49). 42002–42016. 41 indexed citations

Bruce, Catherine R., Deborah A. Smith, David W. Rodgers, et al.. (2011). Identification of a Novel Response Regulator, Crr1, That Is Required for Hydrogen Peroxide Resistance in Candida albicans. PLoS ONE. 6(12). e27979–e27979. 10 indexed citations

Smith, Deborah A., Brian A. Morgan, & Janet Quinn. (2010). Stress signalling to fungal stress-activated protein kinase pathways. FEMS Microbiology Letters. 306(1). 1–8. 86 indexed citations

10.

Blagden, Sarah P., David Olmos, Rakesh Kumar Sharma, et al.. (2008). Characterization of BI 6727, a novel Polo-like kinase inhibitor with a distinct pharmacokinetic profile and efficacy in a model of taxane-resistant colon cancer. European Journal of Cancer Supplements. 6. 135–135. 2 indexed citations

11.

Midgley, Rachel, Rachel Kerr, Keith T. Flaherty, et al.. (2007). A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Annals of Oncology. 18(12). 2025–2029. 43 indexed citations

12.

Smith, Deborah A., et al.. (2007). A Single MAPKKK Regulates the Hog1 MAPK Pathway in the Pathogenic FungusCandida albicans. Molecular Biology of the Cell. 18(11). 4603–4614. 92 indexed citations

13.

Burris, Howard A., Herbert I. Hurwitz, Elizabeth Claire Dees, et al.. (2005). Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas. Journal of Clinical Oncology. 23(23). 5305–5313. 503 indexed citations breakdown →

14.

Spector, Neil L., Wenle Xia, Howard A. Burris, et al.. (2005). Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies. Journal of Clinical Oncology. 23(11). 2502–2512. 290 indexed citations

15.

Enjalbert, Brice, Deborah A. Smith, Michael Cornell, et al.. (2005). Role of the Hog1 Stress-activated Protein Kinase in the Global Transcriptional Response to Stress in the Fungal PathogenCandida albicans. Molecular Biology of the Cell. 17(2). 1018–1032. 311 indexed citations

16.

Smith, Deborah A., Susan M. Nicholls, Brian A. Morgan, Alistair J. P. Brown, & Janet Quinn. (2004). A Conserved Stress-activated Protein Kinase Regulates a Core Stress Response in the Human Pathogen Candida albicans. Molecular Biology of the Cell. 15(9). 4179–4190. 219 indexed citations

17.

Bence, Aimee K., Michael Doukas, George A. Davis, et al.. (2004). Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Investigational New Drugs. 23(1). 39–49. 98 indexed citations

18.

Smith, Deborah A., et al.. (1998). Pharmacokinetics and Pharmacodynamics of Zolmitriptan in Patients with Mild to Moderate Hypertension: A Double‐Blind, Placebo‐Controlled Study. The Journal of Clinical Pharmacology. 38(8). 685–693. 15 indexed citations

19.

Smith, Deborah A., et al.. (1983). Potential Benefits of Academic Units in the College Residence Hall: An Issue Revisited.. The Journal of College and University Student Housing. 13(2). 8–13. 2 indexed citations

20.

Smith, Deborah A.. (1980). Redlining, Disinvestment and the Role of Mutual Savings Banks: A Survey of Solutions. The Fordham urban law journal/Fordham urban law journal. 9(1). 89.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact